Literature DB >> 19419700

A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease.

Casey Cook1, Leonard Petrucelli.   

Abstract

The evidence for impairment in the ubiquitin proteasome system (UPS) in Parkinson's disease (PD) is mounting and becoming increasingly more convincing. However, it is presently unclear whether UPS dysfunction is a cause or result of PD pathology, a crucial distinction which impedes both the understanding of disease pathogenesis and the development of effectual therapeutic approaches. Recent findings discussed within this review offer new insight and provide direction for future research to conclusively resolve this debate.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19419700      PMCID： PMC2828612          DOI： 10.1016/j.bbadis.2009.01.012

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN： 0006-3002


  236 in total

1.  Neural activity controls the synaptic accumulation of alpha-synuclein.

Authors:  Doris L Fortin; Venu M Nemani; Susan M Voglmaier; Malcolm D Anthony; Timothy A Ryan; Robert H Edwards
Journal:  J Neurosci       Date:  2005-11-23       Impact factor: 6.167

2.  The axial channel of the 20S proteasome opens upon binding of the PA200 activator.

Authors:  Joaquin Ortega; J Bernard Heymann; Andrey V Kajava; Vicença Ustrell; Martin Rechsteiner; Alasdair C Steven
Journal:  J Mol Biol       Date:  2005-01-26       Impact factor: 5.469

3.  Direct evidence for S-nitrosation of mitochondrial complex I.

Authors:  Lindsay S Burwell; Sergiy M Nadtochiy; Andrew J Tompkins; Sara Young; Paul S Brookes
Journal:  Biochem J       Date:  2006-03-15       Impact factor: 3.857

4.  The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.

Authors:  Christian Johannes Gloeckner; Norbert Kinkl; Annette Schumacher; Ralf J Braun; Eric O'Neill; Thomas Meitinger; Walter Kolch; Holger Prokisch; Marius Ueffing
Journal:  Hum Mol Genet       Date:  2005-12-01       Impact factor: 6.150

5.  Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease.

Authors:  Michael Hsu; Bharath Srinivas; Jyothi Kumar; Rajagopalan Subramanian; Julie Andersen
Journal:  J Neurochem       Date:  2005-03       Impact factor: 5.372

6.  Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function.

Authors:  Cheng Wang; Han Seok Ko; Bobby Thomas; Fai Tsang; Katherine C M Chew; Shiam-Peng Tay; Michelle W L Ho; Tit-Meng Lim; Tuck-Wah Soong; Olga Pletnikova; Juan Troncoso; Valina L Dawson; Ted M Dawson; Kah-Leong Lim
Journal:  Hum Mol Genet       Date:  2005-11-08       Impact factor: 6.150

7.  Glycogen synthase kinase 3beta modulates synphilin-1 ubiquitylation and cellular inclusion formation by SIAH: implications for proteasomal function and Lewy body formation.

Authors:  Eyal Avraham; Raymonde Szargel; Allon Eyal; Ruth Rott; Simone Engelender
Journal:  J Biol Chem       Date:  2005-09-20       Impact factor: 5.157

8.  Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration.

Authors:  Wanli W Smith; Zhong Pei; Haibing Jiang; Darren J Moore; Yideng Liang; Andrew B West; Valina L Dawson; Ted M Dawson; Christopher A Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-13       Impact factor: 11.205

9.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.

Authors:  Andrew B West; Darren J Moore; Saskia Biskup; Artem Bugayenko; Wanli W Smith; Christopher A Ross; Valina L Dawson; Ted M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-03       Impact factor: 11.205

10.  DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity.

Authors:  Wenbo Zhou; Curt R Freed
Journal:  J Biol Chem       Date:  2005-10-14       Impact factor: 5.157
View more
  39 in total

Review 1.  Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?

Authors:  Sagar Kansara; Akash Trivedi; Sheng Chen; Joseph Jankovic; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2012-06-26       Impact factor: 3.575

2.  Improved quantitative mass spectrometry methods for characterizing complex ubiquitin signals.

Authors:  Lilian Phu; Anita Izrael-Tomasevic; Marissa L Matsumoto; Daisy Bustos; Jasmin N Dynek; Anna V Fedorova; Corey E Bakalarski; David Arnott; Kurt Deshayes; Vishva M Dixit; Robert F Kelley; Domagoj Vucic; Donald S Kirkpatrick
Journal:  Mol Cell Proteomics       Date:  2010-11-03       Impact factor: 5.911

3.  Lessons learnt from animal models: pathophysiology of neuropathic lysosomal storage disorders.

Authors:  Kim M Hemsley; John J Hopwood
Journal:  J Inherit Metab Dis       Date:  2010-05-07       Impact factor: 4.982

4.  Analysis of blood-based gene expression in idiopathic Parkinson disease.

Authors:  Ron Shamir; Christine Klein; David Amar; Eva-Juliane Vollstedt; Michael Bonin; Marija Usenovic; Yvette C Wong; Ales Maver; Sven Poths; Hershel Safer; Jean-Christophe Corvol; Suzanne Lesage; Ofer Lavi; Günther Deuschl; Gregor Kuhlenbaeumer; Heike Pawlack; Igor Ulitsky; Meike Kasten; Olaf Riess; Alexis Brice; Borut Peterlin; Dimitri Krainc
Journal:  Neurology       Date:  2017-09-15       Impact factor: 9.910

5.  Compounds that extend longevity are protective in neurodegenerative diseases and provide a novel treatment strategy for these devastating disorders.

Authors:  Sonja K Soo; Paige D Rudich; Annika Traa; Namasthée Harris-Gauthier; Hazel J Shields; Jeremy M Van Raamsdonk
Journal:  Mech Ageing Dev       Date:  2020-06-28       Impact factor: 5.432

6.  Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein.

Authors:  Darius Ebrahimi-Fakhari; Ippolita Cantuti-Castelvetri; Zhanyun Fan; Edward Rockenstein; Eliezer Masliah; Bradley T Hyman; Pamela J McLean; Vivek K Unni
Journal:  J Neurosci       Date:  2011-10-12       Impact factor: 6.167

Review 7.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

8.  Expression analysis of genes of ubiquitin-proteasome protein degradation system in MPTP-induced mice models of early stages of Parkinson's disease.

Authors:  E V Filatova; M I Shadrina; A Kh Alieva; A A Kolacheva; P A Slominsky; M V Ugrumov
Journal:  Dokl Biochem Biophys       Date:  2014-07-04       Impact factor: 0.788

Review 9.  Neurodegenerative disorders and nanoformulated drug development.

Authors:  Ari Nowacek; Lisa M Kosloski; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2009-07       Impact factor: 5.307

10.  GTP-binding inhibitors increase LRRK2-linked ubiquitination and Lewy body-like inclusions.

Authors:  Joseph M Thomas; Xiaobo Wang; Gongbo Guo; Tianxia Li; Bingling Dai; Leslie G Nucifora; Frederick C Nucifora; Zhaohui Liu; Fengtian Xue; Chunfeng Liu; Christopher A Ross; Wanli W Smith
Journal:  J Cell Physiol       Date:  2020-03-17       Impact factor: 6.384
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.